NeuroProfile is committed to the discovery and development of novel therapeutics for the treatment of Central Nervous System (CNS) diseases. The main objective is the identification and commercialization of novel neuronal drug targets (disease-related genes or proteins) for the most important neurodegenerative diseases Alzheimer and Parkinson and for psychiatric disorders such as schizophrenia and depression. Our targets will be the basics for forthcoming drug generations with new mechanisms of action that not only ameliorate the disease symptoms, but potentially prevent or block progression of the disease.
Core Technologies and Services
NeuroProfile's competitive competence is an innovative multi-faceted proprietary nerve cell platform technology with the scope on identifying and validating drug targets involved in
- early stages of disease-relevant processes
- internal defense mechanisms of the nerve cells
Our target screening and validation procedures are based on diverse functional genomics and proteomics technologies.